<DOC>
	<DOCNO>NCT02229396</DOCNO>
	<brief_summary>Study D5553C0003 28-week , randomize , double-blind , active-controlled , multicenter , Phase 3 efficacy safety study 24-week 52-week extension phase simultaneous administration exenatide weekly ( EQW ) 2 mg dapagliflozin 10 mg daily ( QD ) compare EQW 2 mg alone dapagliflozin 10 mg QD alone patient Type 2 diabetes inadequate glycemic control metformin .</brief_summary>
	<brief_title>Phase 3 28-Week Study With 24-Week 52-week Extension Phases Evaluate Efficacy Safety Exenatide Once Weekly Dapagliflozin Versus Exenatide Dapagliflozin Matching Placebo</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Exenatide</mesh_term>
	<criteria>Inclusion criterion Has diagnosis T2DM . Has HbA1c 8.0 % 12.0 % , inclusive , Visit 1 Visit 2 . Treated stable dose metformin ≥1500 mg/day least 2 month prior Screening . Exclusion criterion FPG ≥280 mg/dL ( 15.6 mmol/L ) . Serum calcitonin concentration ≥40 pg/mL ( ≥40 ng/L ) Visit 1 ( Screening ) Clinically significant abnormal free T4 value patient need initiation adjustment thyroid treatment accord investigator . Abnormal thyroid stimulate hormone ( TSH ) value Screening evaluate free T4.Patients clinically significant abnormal free T4 value exclude . Known active proliferative retinopathy . History , currently , acute chronic pancreatitis , triglyceride concentration ≥500 mg/dL ( ≥5.65 mmol/L ) Visit 1 History presence inflammatory bowel disease severe GI disease , particularly may impact gastric emptying , gastroparesis pyloric stenosis . History gastric bypass surgery gastric banding surgery , either procedure planned time period study . Current use gastric balloon also exclude .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>130 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Diabetes Mellitus</keyword>
	<keyword>Exenatide</keyword>
	<keyword>Dapagliflozin</keyword>
	<keyword>Diabetes medication</keyword>
	<keyword>Treatment efficacy</keyword>
	<keyword>Placebo</keyword>
	<keyword>Metabolism</keyword>
	<keyword>Cardiovascular metabolic</keyword>
</DOC>